{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T19:58:59Z","timestamp":1775764739935,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","derm.theclinics.com","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.det.2017.11.010","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T00:51:31Z","timestamp":1513299091000},"page":"151-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Medical Management of Facial Redness in Rosacea"],"prefix":"10.1016","volume":"36","author":[{"given":"Abigail","family":"Cline","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","article-title":"Clinical, cellular, and molecular aspects in the pathophysiology of rosacea","volume":"15","author":"Steinhoff","year":"2011","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"6","key":"10.1016\/j.det.2017.11.010_bib2","first-page":"694","article-title":"Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin","volume":"11","author":"Del Rosso","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.010_bib3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaad.2004.01.048","article-title":"Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea","volume":"50","author":"Wilkin","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.010_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000338693","article-title":"Tacrolimus-induced rosacea-like dermatitis: a clinical analysis of 16 cases associated with tacrolimus ointment application","volume":"224","author":"Teraki","year":"2012","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.det.2017.11.010_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","article-title":"Rosacea\u2014global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group","volume":"25","author":"Elewski","year":"2011","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2017.11.010_bib7","article-title":"Interventions for rosacea","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.det.2017.11.010_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1067\/mjd.2003.308","article-title":"Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies","volume":"48","author":"Thiboutot","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6 Pt 1","key":"10.1016\/j.det.2017.11.010_bib9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0190-9622(99)70085-X","article-title":"A\u00a0comparison of topical azelaic acid 20% cream and topical metronidazole 0.75% cream in the treatment of patients with papulopustular rosacea","volume":"40","author":"Maddin","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.010_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-4632.2004.02283.x","article-title":"Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide\/clindamycin topical gel in the treatment of patients with moderate to severe rosacea","volume":"43","author":"Breneman","year":"2004","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.010_bib11","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies","volume":"12","author":"Fowler","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.010_bib12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/17512433.2014.945910","article-title":"Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea","volume":"7","author":"Tong","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdermsci.2014.04.002","article-title":"Vasoconstriction and anti-inflammatory properties of the selective alpha-adrenergic receptor agonist brimonidine","volume":"75","author":"Piwnica","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"issue":"4","key":"10.1016\/j.det.2017.11.010_bib14","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1124\/mol.109.058057","article-title":"Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment","volume":"76","author":"Huang","year":"2009","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.det.2017.11.010_bib15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.010_bib16","first-page":"699","article-title":"Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea","volume":"13","author":"Jackson","year":"2014","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib17","first-page":"56","article-title":"Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study","volume":"13","author":"Moore","year":"2014","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"2","key":"10.1016\/j.det.2017.11.010_bib18","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2013.10.054","article-title":"Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%","volume":"70","author":"Routt","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.det.2017.11.010_bib19","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jamadermatol.2015.1252","article-title":"Erythema in skin adjacent to area of long-term brimonidine treatment for rosacea: a novel adverse reaction","volume":"151","author":"Gillihan","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib20","first-page":"33","article-title":"Optimizing the use of topical brimonidine in rosacea management: panel recommendations","volume":"14","author":"Tanghetti","year":"2015","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2017.11.010_bib21","series-title":"Allergan announces FDA approval of RHOFADE\u2122 (oxymetazoline hydrochloride) cream, 1% for the topical treatment of persistent facial erythema associated with rosacea in adults","year":"2017"},{"issue":"11","key":"10.1016\/j.det.2017.11.010_bib22","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/archderm.143.11.1369","article-title":"Successful treatment of the\u00a0erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline","volume":"143","author":"Shanler","year":"2007","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","article-title":"Neurovascular and neuroimmune aspects in the pathophysiology of rosacea","volume":"15","author":"Schwab","year":"2011","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"5","key":"10.1016\/j.det.2017.11.010_bib24","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1346-8138.2010.00999.x","article-title":"Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline","volume":"38","author":"Kim","year":"2011","journal-title":"J\u00a0Dermatol"},{"issue":"12","key":"10.1016\/j.det.2017.11.010_bib25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1346-8138.2011.01223.x","article-title":"Pimecrolimus 1% cream for the treatment of rosacea","volume":"38","author":"Kim","year":"2011","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0190-9622(03)02157-1","article-title":"Tacrolimus effect on rosacea","volume":"50","author":"Bamford","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.010_bib27","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1365-2133.2006.07669.x","article-title":"Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial","volume":"156","author":"Weissenbacher","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2017.11.010_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1468-3083.2008.02589.x","article-title":"A\u00a0randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea","volume":"22","author":"Karabulut","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2017.11.010_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1468-3083.2003.00692.x","article-title":"Pimecrolimus: a review","volume":"17","author":"Gupta","year":"2003","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.det.2017.11.010_bib30","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jaad.2009.01.029","article-title":"Rosaceiform dermatitis associated with topical tacrolimus treatment","volume":"62","author":"Fujiwara","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6 Suppl 1","key":"10.1016\/j.det.2017.11.010_bib31","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jaad.2013.04.041","article-title":"Emerging therapies in rosacea","volume":"69","author":"Layton","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.010_bib32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000066430","article-title":"Ivermectin-responsive demodex infestation during human immunodeficiency virus infection","volume":"205","author":"Aquilina","year":"2002","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.det.2017.11.010_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0190-9622(99)70022-8","article-title":"Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream","volume":"41","author":"Forstinger","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2017.11.010_bib34","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/jdv.13801","article-title":"Efficacy and safety of permethrin 5% topical gel vs. placebo for rosacea: a double-blind randomized controlled clinical trial","volume":"30","author":"Raoufinejad","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2017.11.010_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000065849","article-title":"Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea. A randomized double-blind placebo-controlled study","volume":"205","author":"Kocak","year":"2002","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib36","first-page":"20","article-title":"Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton","volume":"2","author":"Bikowski","year":"2009","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.010_bib37","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein","year":"2014","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.010_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/09546634.2014.991672","article-title":"An emerging treatment: topical ivermectin for papulopustular rosacea","volume":"26","author":"Abokwidir","year":"2015","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"9","key":"10.1016\/j.det.2017.11.010_bib39","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-4632.2006.02924.x","article-title":"Ivermectin treatment of three cases of demodecidosis during human immunodeficiency virus infection","volume":"45","author":"Clyti","year":"2006","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.010_bib40","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.010_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/archderm.1994.01690030051008","article-title":"A\u00a0comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea","volume":"130","author":"Ertl","year":"1994","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.010_bib42","first-page":"333","article-title":"A\u00a0randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks","volume":"11","author":"Chang","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"12","key":"10.1016\/j.det.2017.11.010_bib43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.1966.tb12168.x","article-title":"A\u00a0clinical trial of tetracycline in rosacea","volume":"78","author":"Sneddon","year":"1966","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2017.11.010_bib44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1540-9740.2003.03014.x","article-title":"Subantimicrobial dose doxycycline for acne and rosacea","volume":"2","author":"Bikowski","year":"2003","journal-title":"Skinmed"},{"issue":"5","key":"10.1016\/j.det.2017.11.010_bib45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"56","author":"Del Rosso","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2017.11.010_bib46","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/jid.2012.14","article-title":"Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin","volume":"132","author":"Kanada","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib47","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/jidsymp.2011.4","article-title":"Rosacea as a disease of cathelicidins and skin innate immunity","volume":"15","author":"Yamasaki","year":"2011","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"3","key":"10.1016\/j.det.2017.11.010_bib48","first-page":"16","article-title":"Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"key":"10.1016\/j.det.2017.11.010_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2012.04.017","article-title":"Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective beta-adrenergic blocker","volume":"67","author":"Hsu","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1346-8138.12687","article-title":"Propranolol, doxycycline and combination therapy for the treatment of rosacea","volume":"42","author":"Park","year":"2015","journal-title":"J\u00a0Dermatol"},{"issue":"11","key":"10.1016\/j.det.2017.11.010_bib51","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/archdermatol.2011.204","article-title":"Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea","volume":"147","author":"Hsu","year":"2011","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.det.2017.11.010_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003262.pub4","article-title":"Interventions for rosacea","author":"van Zuuren","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"5 Suppl","key":"10.1016\/j.det.2017.11.010_bib53","first-page":"7","article-title":"An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads)","volume":"86","author":"Webster","year":"2010","journal-title":"Cutis"},{"issue":"6","key":"10.1016\/j.det.2017.11.010_bib54","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/120347541201600615","article-title":"Isotretinoin for the treatment of granulomatous rosacea: case report and review of the literature","volume":"16","author":"Rallis","year":"2012","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"9","key":"10.1016\/j.det.2017.11.010_bib55","first-page":"54","article-title":"Use of oral isotretinoin in the management of rosacea","volume":"4","author":"Park","year":"2011","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"7","key":"10.1016\/j.det.2017.11.010_bib56","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archderm.134.7.884","article-title":"Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea","volume":"134","author":"Erdogan","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2017.11.010_bib57","unstructured":"Irvine C, Kumar P, Marks R. Isotretinoin in the treatment of rosacea and rhinophyma. London: 1988."},{"issue":"1","key":"10.1016\/j.det.2017.11.010_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2340\/00015555-1204","article-title":"Rosacea treatment with intermediate-dose isotretinoin: follow-up with erythema and sebum measurements","volume":"92","author":"Uslu","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.det.2017.11.010_bib59","first-page":"26","article-title":"Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea","volume":"5","author":"Del Rosso","year":"2012","journal-title":"J\u00a0Clin Aesthet Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863517301687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863517301687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T03:24:18Z","timestamp":1535167458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863517301687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0733863517301687"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2017.11.010","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Management of Facial Redness in Rosacea","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2017.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}